Daclizumab a novel corticosteroid-sparing therapy for asthma?
In asthma, inhaled corticosteroids are not always able to maintain an optimal therapeutic control despite being used at high doses; other anti-inflammatory therapies are needed. Several such therapies, including daclizumab, are currently under evaluation. To discuss the results of study on daclizumab in asthma patients. Analysis of efficacy and safety data from a randomised placebo-controlled study performed in patients with moderate to severe asthma and suboptimal control under high doses of inhaled corticosteroids. Daclizumab demonstrated significant efficacy and its further clinical evaluation in asthma is supported by these results.